Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edith Borcoman

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
Bulletin Du Cancer|June 18, 2026
[Perioperative pembrolizumab in locally advanced head and neck cancer]Andrea Marques, Edith Borcoman
Therapeutic Advances in Medical Oncology|June 14, 2017
Pembrolizumab in cervical cancer: latest evidence and clinical usefulnessEdith Borcoman, Christophe Le Tourneau
Current Opinion in Oncology|July 2, 2016
Antibody drug conjugates: the future of chemotherapy?Edith Borcoman, Christophe Le Tourneau
Annals of Translational Medicine|January 13, 2021
Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancerEdith Borcoman, Christophe Le Tourneau
Future Oncology (London, England)|December 12, 2017
Precision medicine strategies in oncology: mixed approaches to matched therapiesEdith Borcoman, Christophe Le Tourneau
International Journal of Molecular Sciences|June 2, 2019
Hyperprogression under ImmunotherapyMaxime Frelaut, Christophe Le Tourneau, Edith Borcoman
Cancers|June 2, 2021
Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell CarcinomaEdith Borcoman, Gregoire Marret, Christophe Le Tourneau
Nature Medicine|May 1, 2019
Molecular profiling in precision medicine oncologyChristophe Le Tourneau, Edith Borcoman, Maud Kamal
Current Opinion in Oncology|March 26, 2023
Window-of-opportunity clinical trials for biomarker discovery in head and neck squamous cell carcinomaGrégoire Marret, Edith Borcoman, Christophe Le Tourneau
Expert Opinion on Biological Therapy|July 20, 2019
Pembrolizumab for the treatment of cervical cancerGrégoire Marret, Edith Borcoman, Christophe Le Tourneau
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
Bulletin Du Cancer|June 18, 2026
[Perioperative pembrolizumab in locally advanced head and neck cancer]Andrea Marques, Edith Borcoman
Therapeutic Advances in Medical Oncology|June 14, 2017
Pembrolizumab in cervical cancer: latest evidence and clinical usefulnessEdith Borcoman, Christophe Le Tourneau
Current Opinion in Oncology|July 2, 2016
Antibody drug conjugates: the future of chemotherapy?Edith Borcoman, Christophe Le Tourneau
Annals of Translational Medicine|January 13, 2021
Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancerEdith Borcoman, Christophe Le Tourneau
Future Oncology (London, England)|December 12, 2017
Precision medicine strategies in oncology: mixed approaches to matched therapiesEdith Borcoman, Christophe Le Tourneau
International Journal of Molecular Sciences|June 2, 2019
Hyperprogression under ImmunotherapyMaxime Frelaut, Christophe Le Tourneau, Edith Borcoman
Cancers|June 2, 2021
Paradigm Change in First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell CarcinomaEdith Borcoman, Gregoire Marret, Christophe Le Tourneau
Nature Medicine|May 1, 2019
Molecular profiling in precision medicine oncologyChristophe Le Tourneau, Edith Borcoman, Maud Kamal
Current Opinion in Oncology|March 26, 2023
Window-of-opportunity clinical trials for biomarker discovery in head and neck squamous cell carcinomaGrégoire Marret, Edith Borcoman, Christophe Le Tourneau
Expert Opinion on Biological Therapy|July 20, 2019
Pembrolizumab for the treatment of cervical cancerGrégoire Marret, Edith Borcoman, Christophe Le Tourneau
Pageof 6